{
    "nct_id": "NCT04586426",
    "official_title": "A Phase 1b/2 Dose Escalation and Expansion Study of the Combination of the Bispecific T Cell Redirection Antibodies Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma",
    "inclusion_criteria": "* Documented initial diagnosis of multiple myeloma according to International Myeloma Working Group (IMWG) diagnostic criteria\n* Part 1 and 2: Participant could not tolerate or has disease that is relapsed or refractory to established therapies, including the last line of therapy. Part 3: (a) Relapsed or refractory disease, and exposed to a PI, IMiD, and an anti-CD38 mAb; (b) Documented evidence of progressive disease based on investigator's determination of response by IMWG criteria on or after their last regimen\n* Part 1 and Part 2: Eastern Cooperative Oncology Group (ECOG) performance status grade of 0 or 1 at screening and immediately before the start of study drug administration. Part 3: ECOG performance status grade of 0, 1, or 2 at screening and immediately before the start of study drug administration\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* All Parts: Targeted therapy, epigenetic therapy, or treatment with an investigational treatment or an invasive investigational medical device within 21 days or at least 5 half-lives, whichever is less. Part 3: prior BCMA targeted bispecific antibody therapy; prior GPRC5D targeted therapy\n* All Parts: Allogeneic stem cell transplant within 6 months before the first dose of study treatment.\n* All Parts: Central nervous system involvement or clinical signs of meningeal involvement of multiple myeloma.\n* All Parts: Active plasma cell leukemia (greater than [>]2.0*10^9/L plasma cells by standard differential), WaldenstroÌˆm's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M- protein, and skin changes), or primary amyloid light chain amyloidosis",
    "miscellaneous_criteria": ""
}